Login to Your Account

EMA plan would foster tissue therapy advancements and cut regulatory red tape

By Nuala Moran
Staff Writer

Monday, October 23, 2017

LONDON – The EMA has pledged better support for the development of advanced tissue medicinal products (ATMPs) based on cells, genes or tissues, in response to long-running and repeated complaints by industry that the regulation is overcomplex and in some cases, inappropriate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription